Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O15394

UPID:
NCAM2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O15394; A8MQ06; B7Z841; Q7Z7F2

BACKGROUND:
The Neural cell adhesion molecule 2, encoded by the gene O15394, is instrumental in the development of the olfactory system. It ensures the accurate projection of olfactory axons, which is crucial for the sense of smell. This protein's function underscores its importance in neural cell adhesion and axonal pathfinding.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Neural cell adhesion molecule 2 offers promising avenues for therapeutic development. As it plays a critical role in neural connectivity, targeting NCAM2 could lead to innovative treatments for disorders related to neural miswiring or sensory deficits.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.